Alloantibodies in heart transplantation

详细信息    查看全文

• 作者：Eric K. Ho ; George Vlad ; Adriana I. Colovai ; E. Rodica Vasilescu ; Joseph Schwartz ; Hugo Sondermeijer ; Elizabeth Burke ; Charles C. Marboe ; Silviu Itescu ; Nicole Suciu-Foca ; Donna Mancini
• 关键词：Heart transplantation ; Anti-HLA antibodies ; Allosensitization ; Graft survival
• 刊名：Human Immunology
• 出版年：2009
• 出版时间：October 2009
• 年：2009
• 卷：70
• 期：10
• 页码：825-829
• 全文大小：380 K

文摘

The presence of complement fixing anti–human leukocyte antigen (HLA) antibodies in the circulation of organ transplant recipients may result in heart allograft rejection. Here, we assessed the clinical impact of pre- and post-transplantation allosensitization on long-term survival of heart allografts. Sequential samples of sera from heart allograft recipients were screened pretransplantation for panel reactive antibodies using the complement-dependent cytotoxicity test. Patients were monitored post-transplantation for donor specific anti-HLA class I and class II antibodies. Kaplan-Meier graft survival plots were generated to analyze the effect of anti-HLA antibodies on transplantation outcomes. Statistical analysis showed that the post-transplantation development of alloantibodies was a significant risk factor that was associated with low long-term survival rates; in contrast, recipients' gender, age, previous transplantations, and degree of HLA matching with the donor had no effect on long-term survival. The presence in pretransplantation sera of antibodies against more than 10 % of the HLA reference panel (PRA >10 % ) was associated with AMR and with a relatively lower rate of graft survival after 1 year but did not affect 10-year survival. The present data underline the importance of monitoring the development of anti-HLA antibodies as a tool for early diagnosis and treatment of AMR.